Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

36.10
Delayed Data
As of 3:59pm ET
 +0.70 / +1.98%
Today’s Change
20.68
Today|||52-Week Range
41.20
+25.17%
Year-to-Date
Valeant Reports Positive Results on Psoriasis Drug Siliq
Oct 13 / Zacks.com - Paid Partner Content
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
Oct 09 / Zacks.com - Paid Partner Content
Lilly's Verzenio Gets Priority Review in First-Line Setting
Oct 13 / Zacks.com - Paid Partner Content
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
Oct 09 / Zacks.com - Paid Partner Content
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
Oct 12 / Zacks.com - Paid Partner Content
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status
Oct 05 / Zacks.com - Paid Partner Content
Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA
Oct 11 / Zacks.com - Paid Partner Content
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
Oct 05 / Zacks.com - Paid Partner Content
Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
Oct 10 / Zacks.com - Paid Partner Content
Celsion's Immunotherapy Candidate Impresses, Stock Surges
Oct 04 / Zacks.com - Paid Partner Content
Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
Oct 10 / Zacks.com - Paid Partner Content
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
Oct 04 / Zacks.com - Paid Partner Content
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
Oct 09 / Zacks.com - Paid Partner Content